Alexandria Real Estate Equities, Inc. (ARE) Stock Analysis
Alexandria is a distressed but high-quality life science real estate leader: battered by oversupply and weak biotech leasing, yet trading at deep-value levels against irreplaceable Megacampus assets and a well-covered dividend.
Overview
Alexandria is the pioneering life science REIT, owning mission-critical lab and Megacampus assets in North America’s premier biotech clusters. Its high-credit tenant base, long leases, specialized infrastructure, and cluster model create a durable moat. However, the company is undergoing a difficult 2026 reset as pandemic-era oversupply, weak biotech leasing, falling occupancy, and negative re-leasing spreads pressure growth. Management is preserving balance-sheet strength through major dispositions and disciplined capital allocation.